Skip Navigation

ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Shane Roller

Shane Roller

Dr. Shane Roller earned his Ph.D. in chemistry from the University of Virginia, studying the bioactivation of the antiepileptic drug, felbamate.  Upon graduating in 2003, Shane spent 4 years in the Department of Drug Metabolism at Merck Research Laboratories before joining GlaxoSmithKline in 2007.  At GlaxoSmithKline, Shane became the DMPK leader for the Enteroendocrine Discovery Unit, whose focus was the discovery of peptide therapeutics to treat metabolic diseases.  After leaving GlaxoSmithKline in 2015, Shane co-founded Phoundry Pharmaceuticals, a biotech startup focused on the discovery of peptide therapeutics, where he now serves as the Director of DMPK.